Sectors
DMRA
Damora Therapeutics, Inc.
22.59
1 x 22.94
2 x 31.50
bid
ask
-
0.19
0.83%
2 @ 07:30 PM
22.19 -0.40 (1.77%)
| Ytd | -1.83% | |
| 1y | 687.11% |
22.02
day range
23.44
2.87
52 week range
34.14
| Open | 22.94 | Prev Close | 22.78 | Low | 22.02 | High | 23.44 | Mkt Cap | 1.39B |
| Vol | 3.32M | Avg Vol | 594.99K | EPS | -0.26 | P/E | N/A | Forward P/E | -10.54 |
| Beta | 1.47 | Short Ratio | 12.41 | Inst. Own | 105.72% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 29.46 | 200-d Avg | 26.39 | 1yr Est | 44.67 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-05 | 2026-09 | -0.52 | N/A | N/A | N/A |
| 2026-08-11 | 2026-06 | -0.41 | -0.39 | 0.02 | 5.79% |
| 2026-05-12 | 2026-03 | -0.21 | -0.62 | -0.41 | -195.24% |
| 2026-03-18 | 2025-12 | -0.14 | -3.24 | -3.1 | -2216.35% |
| 2025-11-06 | 2025-09 | -0.1 | -2.36 | -2.26 | -2337.76% |
| 2025-08-05 | 2025-06 | 0 | -2.6 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-30 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-07-27 | Jefferies | Upgrade | Buy | |
| 2026-07-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-06-12 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-06-11 | HC Wainwright & Co. | Upgrade | Buy | |
| 2026-05-28 | Wedbush | Upgrade | Outperform |
Profile
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-02-08 | BRUNO JULIANNE | Director | 137.03K | Conversion of Exercise of derivative security |
| 2026-02-08 | FAIRMOUNT FUNDS MANAGEMENT LLC | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2026-01-01 | FIRMANI LORI | Chief Financial Officer | 931.00 | Sale |
| 2026-01-04 | HEWES LEMUEL BECKER | Officer | 264.63K | Stock Award(Grant) |
| 2026-03-29 | JARRETT A JENNIFER | Chief Executive Officer | 500.00K | Stock Award(Grant) |
| 2026-01-04 | SATTARZADEH SHERWIN | Chief Operating Officer | 190.38K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Price (T.Rowe) Associates Inc | 48.74K | 1.10M | 0.08% |
| 2026-06-29 | Rothschild Investment LLC | 34.00 | 768.00 | 0.00% |
| 2026-06-29 | Harbour Investments, Inc. | 40.00 | 903.00 | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-07-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.83M | 41.26M | 2.96% |
| 2026-07-30 | iShares Trust-iShares Russell 2000 ETF | 1.34M | 30.17M | 2.16% |
| 2026-07-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 702.24K | 15.86M | 1.14% |
| 2026-07-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 537.65K | 12.15M | 0.87% |
| 2026-07-30 | Fidelity Select Portfolios-Select Health Care Portfolio | 500.00K | 11.30M | 0.81% |
| 2026-07-30 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 454.56K | 10.27M | 0.74% |